Loading clinical trials...
Loading clinical trials...
A Multi-centre, Randomised Controlled Trial Comparing Fecal Microbiota Transplantation to Placebo in an Expanded Ulcerative Colitis Population: a Feasibility Study (FRONTIER-UC)
This is a multi-centre, randomised controlled trial comparing fecal microbiota transplantation to placebo in an expanded ulcerative colitis population: a feasibility study (FRONTIER-UC) to determine whether a full-scale randomized controlled trial (RCT) to investigate fecal microbiota transplantation (FMT) in ulcerative colitis (UC) is feasible.
This is a randomized, double blind, placebo-controlled trial for UC patients with active disease. Participants will be grouped into one of two categories 1. Add to current therapy (i.e., adjunct therapy) or 2. Initiate or switch to a new advanced agent (i.e., co-administration) The study will recruit 85 outpatients at 3 Canadian healthcare centres
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University of Calgary
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
Start Date
March 1, 2026
Primary Completion Date
March 1, 2028
Completion Date
December 1, 2028
Last Updated
February 10, 2026
85
ESTIMATED participants
Lyophilized Fecal Microbiota Transplantation (LFMT)
OTHER
Placebo
OTHER
Lead Sponsor
University of Alberta
Collaborators
NCT06237452
NCT06226883
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions